Publications by authors named "K Borkett"
Background: Remimazolam is a new benzodiazepine for procedural sedation and general anaesthesia. The aim of this study was to characterise its pharmacokinetic properties and safety in renally and hepatically impaired subjects.
Methods: Two separate trials were conducted in patients with hepatic (n=11) or renal impairment (n=11) compared with matched healthy subjects (n=9 and n=12, respectively).
Background And Objectives: Remimazolam is a new ultra-short-acting benzodiazepine currently being developed for intravenous use in procedural sedation, general anaesthesia, and intensive care unit sedation. Benzodiazepines represent a drug class associated with drug-facilitated sexual assaults, especially in combination with alcohol. Two clinical trials were designed to evaluate the oral bioavailability and pharmacokinetics/pharmacodynamics of remimazolam and to assess the potential for remimazolam misuse in drug-facilitated sexual assaults via oral ingestion.
View Article and Find Full Text PDFArticle Synopsis
- Remimazolam (RMZ) is a new fast-acting intravenous benzodiazepine, and this trial aimed to compare its abuse potential with that of midazolam (MDZ) and a placebo in healthy drug users aged 18-55.
- The study found that while both RMZ and MDZ produced significant effects on drug liking and sedation compared to placebo, RMZ had a shorter duration of action and lower scores for overall effects and willingness to use the drug again compared to MDZ.
- The researchers concluded that RMZ's abuse potential is comparable to or lower than MDZ, which is known to have low intravenous abuse potential.
Article Synopsis
- Remimazolam is being tested as a fast-acting sedative for procedures like colonoscopies, with this trial being the fourth study focused on its use in procedural sedation.
- The trial involved 162 patients aged 18 to 70, comparing the efficacy and safety of remimazolam to midazolam, with results showing over 92% success in the remimazolam group compared to 75% for midazolam.
- The findings indicated that remimazolam has a promising safety profile and effectiveness, prompting the need for further phase III trials to confirm these results.
Background: This exploratory study was the first study of remimazolam in patients to assess the safety and efficacy of different single doses for procedural sedation.
Methods: Patients scheduled to undergo a diagnostic upper gastrointestinal endoscopy were randomized to receive 1 of 3 doses of remimazolam or midazolam (25 per group) in a double-blind manner. After a single dose of study drug to achieve sedation, patients underwent gastroscopy.